Obeseマウスに対するメラトニンの抗酸化効果
Luiza Martins Longaretti1, Marina Lummertz Magenis1, Adriani Paganini Damiani1
1Laboratory of Translational Biomedicine, Graduate Program of Health Sciences, University of Southern Santa Catarina - UNESC, Criciúma, SC, Brazil.
Mutagenesis
|February 10, 2026
まとめ
メラトニン(MEL)補給は、高脂肪カフェテリア食(CAF)を与えられたマウスの肥満誘発性の炎症、DNA損傷、およびインスリン抵抗性を効果的に軽減しました。この研究はMELを強調しています
科学分野:
- 生化学
- 遺伝学
- 栄養科学
背景:
- 超加工食品の消費に関連する肥満率の上昇。
- 肥満は抗酸化防御を損ない、DNA損傷のリスクを高めます。
- メラトニン(MEL)は潜在的な抗酸化および抗炎症効果を示します。
研究 の 目的:
- カフェテリア食(CAF)を摂取したマウスにおける生化学的、遺伝毒学的、および炎症マーカーに対するMELの影響を評価する。
- 肥満関連合併症の軽減におけるMELの役割を調査する。
主な方法:
- 標準食(SD)またはCAFを17〜21週間摂取させた60匹のオスマウス。
- 様々な期間のMEL補給を受けたグループ。
- DNA損傷(コメットアッセイ、小核試験)、脂質プロファイル、肝機能、炎症マーカー(TNF-α、IL-10)、グルコース、およびインスリン耐性を評価。
- ウェスタンブロットによる酸化ストレスとDNA修復経路を分析した。
主要な成果:
- CAF食は炎症、脂質/肝臓プロファイルの異常、DNA損傷、およびインスリン抵抗性を誘発しました。
- 17週間のMEL補給はCAF誘発性の変化を逆転させました。
- MELはCAF関連の酸化ストレスと組織損傷を軽減しました。
- MELはDNA修復タンパク質を調節し、遺伝毒性を軽減しました。
結論:
- メラトニン(MEL)は、肥満関連の損傷に対する強力な抗酸化剤として作用します。
- MEL補給は、肥満に関連する生化学的および遺伝的変化を軽減する可能性を示しています。
- MELは肥満合併症の管理のための有用な治療戦略となる可能性があります。
関連する概念動画
Obesity
1.4K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.4K
Drug Dosing: Obese Patients
269
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
269
Buffer Effectiveness
55.5K
Buffer solutions do not have an unlimited capacity to keep the pH relatively constant . Instead, the ability of a buffer solution to resist changes in pH relies on the presence of appreciable amounts of its conjugate weak acid-base pair. When enough strong acid or base is added to substantially lower the concentration of either member of the buffer pair, the buffering action within the solution is compromised.
The buffer capacity is the amount of acid or base that can be added to a given volume...
The buffer capacity is the amount of acid or base that can be added to a given volume...
55.5K
Framing Effects
8.0K
Information is everywhere and its presentation—such as how and when items are presented—can impact our perceptions and decisions surrounding the info. This broad concept umbrellas framing effects—influences that occur due to the way information is framed in its appearance, whether it’s purely the order or the specific wording of a message. Let’s take a look at numerous ways in which two versions of something can objectively say the same thing, yet we respond in...
8.0K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
293
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
293
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
194
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
194


